Sentry BioPharma Services Contracted to Store and Distribute Vaccines for The Centers for Disease Control & Prevention

Sentry BioPharma Services Contracted to Store and Distribute Vaccines for The Centers for Disease Control & Prevention

Sentry to Store and Distribute Influenza Vaccine for CDC's National Strategic Reserve
INDIANAPOLIS, Feb. 23, 2010 - Sentry BioPharma Services announced today that The Centers for Disease Control & Prevention (CDC) selected Sentry to store and distribute influenza vaccine in support of its national strategic reserve. Sentry will warehouse and distribute vaccine from its cGMP, FDA-registered facility located in Indianapolis, Ind. Sentry's vast experience storing and transporting regulated, temperature-sensitive pharmaceutical products will ensure product integrity, supply chain security and fast, efficient distribution of the disease-preventing vaccines.

"Sentry's vaccine storage and distribution services are specifically designed to support government entities, hospitals and public health care agencies," said Jennifer Marcum, Sentry's chief executive officer. "Sentry has a history of supporting the CDC for vaccine distribution needs that require temperature maintenance, robust quality programs and tailored distribution methodology."

Sentry's vaccine storage and distribution service was designed to protect the efficacy of vaccine inventories throughout the supply chain. The company has the expertise, facility, personnel and protocols to securely store, accurately track and quickly transport vaccines in the continental United States and beyond. Sentry's contracted services are ideally suited for both private and public entities that may require managing vaccine, pharmaceutical and biologic products. Sentry's facility, systems and processes meet the CDC's recommendations for proper vaccine storage and handling procedures (http://www.cdc.gov/vaccines/pubs/vac-mgt-book.htm). Additionally, the company holds the appropriate local, state and federal licenses and accreditations for safely handling and transporting commercially approved drug products.

About Sentry BioPharma Services

Sentry BioPharma Services maintains cGMP temperature-controlled storage, FDA labeling capability, distribution licenses and an active Foreign Trade Zone status to exclusively serve the global pharmaceutical, biotechnology and health care industries. Its facilities, infrastructure and services are specifically designed to meet the warehousing, packaging, logistics and contract service needs of pharmaceutical and biotech firms, health care providers and suppliers, contract research organizations (CROs), contract manufacturing organizations (CMOs), wholesalers, distributors and government entities.

Sentry's management team offers expertise in cold chain storage and logistics, quality assurance, pharmaceutical packaging and kitting development. Sentry also offers strategic solutions for domestic and international transportation and logistics as well as end-to-end import and export management. The company's validated processes and inventory tracking systems are FDA compliant, adhere to current Good Manufacturing Practices (cGMPs) and comply with stringent standard operating procedures (SOP) outlined in Sentry's Validation Master Plan. Sentry is VAWD(R) accredited, which ensures its storage, handling and distribution methods meet the recognized guidelines of the National Association of Board of Pharmacy(R). The company is privately held and strategically headquartered in Indianapolis, Ind. For more information about the company, please visit http://www.sentrybps.com or call (866) 757-7400.

MEDIA CONTACT

Mike Lewis
[email protected]
(317) 856-5889

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.